// App-Quantinova.ai

1897 : Successful Therapy Reduction in NCI Standard Risk (SR) Highly Favorable Subgroup of Childhood Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Mayada Abu Shanap

Principal Investigators

  • Iyad Sultan

  • Amal Abu-Ghosh

  • Hasan Hashem

  • Nazmi Kamal

  • Rawad Rihani

Medical Centers

  • Pediatric Department, King Hussein Cancer center (KHCC), Amman, Jordan

  • Pediatric Department, King Hussein Cancer center (KHCC), Amman, Jordan

  • Pediatric Department, King Hussein Cancer center (KHCC), Amman, Jordan

  • Department of Pediatrics, King Hussein Cancer Center, Amman, OH, Jordan

  • Pediatric Department, King Hussein Cancer center (KHCC), Amman, Jordan

Locations

  • Jordan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • ETV6-RUNX1

  • Histone-lysine N-methyltransferase 2A

  • DNA index

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Vincristine

  • Doxorubicin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved